The current gold standard diagnostic modalities for AD include expensive and largely inaccessible imaging modalities such as positron emission tomography (PET) and invasive collections of cerebrospinal fluid (CSF) by lumbar puncture to measure levels of Aβ and hyperphosphorylated tau (Dubois et al., 2021). The gene discussed is MAPT; the disease is Alzheimer disease.